ACE and pulmonary arterial hypertension: Although preclinical studies show ACE inhibitors (52,53), angiotensin receptor blockers (54,55), and aldosterone antagonists (56) attenuate the development of RVH, fibrosis, and RV dysfunction, this occurs in the setting of less severe PAH, so the direct effects on the RV are not definitively understood.